Derms on Drugs

In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, and is this better access or the beginning of the robot takeover?

Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.

Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pricey cosmetic vial may not contain what it claims.

Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the morning actually grow more hair—or just raise more eyebrows?

Dr. Marc Serota makes the case for targeted lab testing in CSU—but the Derms worry it may open a can of worms. The Chronic Urticaria Index gets a closer look, shotgun allergy panels get nowhere—but does he convince the Derms?

After 70,000 virtual consults, Dr. Joe English knows what a photo can—and can’t—tell you. He joins the Derms to talk diagnostic curveballs, hospital saves, and bringing dermatology where there’s no dermatologist in sight.

Three papers, three very different reactions: a Treg-boosting AD drug that may be too clever for its own good, a Steri-Strip trick you can use tomorrow, and Rinvoq alopecia data that have the Derms calling game changer.

Convince the Derms on Drugs makes its debut with Dr. Christopher Sayed making the case for earlier systemic treatment in HS. Can he convince the Derms to act before recurring lesions become tunnels, scars, and damage no medication can undo?

Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hiding in your patient’s shampoo.

Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clot risk may depend on the disease.